【摘要】 目的 探討卵巢兩性母細胞瘤的臨床及病理組織學(xué)特征。 方法 觀察總結(jié)2004年3月-2008年3月6例卵巢兩性母細胞瘤的臨床及病理學(xué)特征，以及免疫組化染色結(jié)果。 結(jié)果 患者以月經(jīng)紊亂、閉經(jīng)、絕經(jīng)后陰道出血為主要臨床表現(xiàn)。腫瘤含兩種成分，即顆粒細胞和Sertoli-Leydig細胞，兩者均呈成熟性的組織學(xué)形態(tài)，1例伴有異源性分化成分。6例腫瘤呈α-inhibin和vimentin強陽性，3例呈CD99陽性，5例呈calretinin陽性，2例的Sertoli細胞呈CK陽性。4例患者有隨訪資料，隨訪期14～60個月，均無瘤存活。 結(jié)論 兩性母細胞瘤以內(nèi)分泌異常相關(guān)癥狀為主要臨床表現(xiàn)，大部分患者診斷時處于臨床1期，預(yù)后較好。對診斷為兩性母細胞瘤的患者應(yīng)進行長期的臨床隨訪。
【Abstract】 Objective To observe the clinical pathologic and immunophenotypic features of gynandroblastoma. Methods The pathologic samples of six patients with gynandroblastoma from March 2004 to March 2008 were observed and analyzed. Immuohistochemistry staining was performed by SP method using antibodies of α-inhibin,CD99,Vimentin,Calretinin,CK,EMA. Results The main clinical features included menstrual disorders, amenorrhea, and postmenopausal bleeding. The tumor was composed of ranulose cells and Sertoli cells, both of which were well differentiated. Strongly positive expression of α-inhibin and vimentin was found in all the patients, while CD99 (+) was in three, calretinin (+) was in five, and CK (+) of Sertoli cells was in two. Four patients were followed up for 14-60 months and all were tumor free. Conclusion The main clinical features of gynandroblastoma are estrogenic or androgenic manifestations. Nearly all the patients are diagnosed in stage 1 and have a good prognosis. Patients with gynandroblastoma should be followed up for a long period.
引用本文： 何艷梅,江煒,李雷,徐煉,楊開選. 卵巢兩性母細胞瘤臨床病理分析. 華西醫(yī)學(xué), 2010, 25(10): 1862-1864. doi: 復(fù)制
| 1. | Tavassoéli FA, Devilee P. World Health Organization classi-fication of tumors: pathology and genetics of tumors of the breast and female genital organs[M]. International Agency for Research on Can cerstaff, 2003. |
| 2. | Roth LM. Recent advances in the pathology and classification of ovarian sex cord-stromal tumors[J]. Int J Gynecol Pathol, 2006, 25(3): 199-215. |
| 3. | Chivukula M, Hunt J, Carter G, et al. Recurrent gynandrob-lastoma of ovary-a case report: a molecular and immunohistoch-emical analysis[J]. Int J of Gynecol Pathol, 2007, 26(1): 30-33. |
| 4. | Vang R, Herrmann ME, Tavassoli FA. Comparative immun-ohistochemical analysis of ranulose and sertoli components in ovarian sex cord-stromal tumors with mixed differentiation: potential implications for derivation of sertoli differentiation in ovarian tumors[J]. Int J Gynecol Pathol, 2004, 23(2): 151-161. |
| 5. | Kato N, Fukase M, Ono I, et al. Sertoli-stromal cell tumor of the ovary: immunohistochemical, ultrastructural, and genetic studies[J]. Hum Pathol, 2001, 32(8): 796-802. |
- 1. Tavassoéli FA, Devilee P. World Health Organization classi-fication of tumors: pathology and genetics of tumors of the breast and female genital organs[M]. International Agency for Research on Can cerstaff, 2003.
- 2. Roth LM. Recent advances in the pathology and classification of ovarian sex cord-stromal tumors[J]. Int J Gynecol Pathol, 2006, 25(3): 199-215.
- 3. Chivukula M, Hunt J, Carter G, et al. Recurrent gynandrob-lastoma of ovary-a case report: a molecular and immunohistoch-emical analysis[J]. Int J of Gynecol Pathol, 2007, 26(1): 30-33.
- 4. Vang R, Herrmann ME, Tavassoli FA. Comparative immun-ohistochemical analysis of ranulose and sertoli components in ovarian sex cord-stromal tumors with mixed differentiation: potential implications for derivation of sertoli differentiation in ovarian tumors[J]. Int J Gynecol Pathol, 2004, 23(2): 151-161.
- 5. Kato N, Fukase M, Ono I, et al. Sertoli-stromal cell tumor of the ovary: immunohistochemical, ultrastructural, and genetic studies[J]. Hum Pathol, 2001, 32(8): 796-802.